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Current literature suggests that prescribing of secondary
preventive therapy has not been maximized which would
reduce the occurrence and cost of secondary fracture.
Additionally, patient acceptance of treatment alternatives
has not been maximized due to the administration com-
plexity and potential side effects of bisphosphonates.
Alternative agents with osteoporotic beneﬁts may be used
in some women to increase patient adherence. Addition-
ally, patient acceptance and adherence may increase after
an osteoporotic incident (fracture or vertebral collapse).
The purpose of this study was to assess compliance rates
through reﬁll adherence with bisphosphonates vs. alter-
native osteoporotic treatments (estrogen replacement
therapy, salmon calcitonin, or raloxifene) in primary and
secondary prevention among women.
METHODS: Members of a Southeastern Michigan
managed care organization were retrospectively identiﬁed
with pharmacy claims by those receiving bisphospho-
nates, estrogen replacement therapy, salmon calcitonin or
raloxifene. Women >45 years of age as of January 1, 2001
were cross-referenced with medical claims for a diagno-
sis of non-traumatic fracture by CPT and ICD-9 codes
between January 1, 1996 to April 30, 2001. Women with
a history of fracture with treatment were classiﬁed as
having secondary treatment prevention; women without
a history were classiﬁed as primary treatment prevention.
RESULTS: Mean adherence rates were 76.32% (±39.12)
in the primary prevention population (n = 653) and
84.91% (±31.08) in the secondary prevention population
(n = 114). The bisphosphonate treatment group’s (n = 78)
mean adherence rate was 77.69% (±33.92); the alterna-
tive treatment group’s (n = 689) rate was 83.86%
(±38.62).
CONCLUSIONS: Treatment associated with secondary
prevention and involving alternative treatments had the
highest adherence rates. Patient adherence and acceptance
should be considered in determining osteoporosis treat-
ment guidelines to ensure those most likely to beneﬁt
receive proper treatment.
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High potency nasal steroids are generally considered 
to be those that can be administered once daily. Most 
clinicians prefer an agent that can be given once daily,
increasing the likelihood of treatment adherence. We
weighted this provider preference highly when we sought
to select one or two nasal steroids for preferred formu-
lary status in our large health system. We analyzed direc-
tions for use of prescriptions for nasal steroid products
to determine the products that appeared to be prescribed
once daily to greater than 90% of patients.
OBJECTIVE: This paper describes the results of a data-
base analysis of nasal corticosteroid dosing patterns in a
large health system.
METHODS: We extracted prescription records from the
Uniformed Services Prescription Database (USPD) for all
nasal corticosteroid inhaler products dispensed between
October 1, 2000 and May 31, 2001. There were 659,000 
prescriptions for 260,971 unique patients in the dataset.
We developed and validated a text parsing algorithm to
analyze directions for use (sigs) associated with each 
prescription. Number of prescribed administration times
per day and number of puffs per administration were 
tabulated for each patient by product.
RESULTS: Of the eleven available formulations, 
three were used once a day in over 90% of patients:
Mometasone aqueous (94.1%), ﬂuticasone (94.6%), and
beclomethasone DS aqueous (91.9%). Three products
(triamcinolone aqueous, triamcinolone aerosol, and
beclomethasone DS aerosol) were used once a day in
80%–90% of patients. Once daily use of the remaining
products ranged from 10% to 62.7%.
CONCLUSION: Three products (mometasone, ﬂuticas-
one and beclomethasone DS aqueous) appeared to be 
prescribed once daily to greater than 90% of patients,
meeting our criteria for preferred formulary status.
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OBJECTIVES: To quantify the magnitude of reduced
productivity in the workplace related to allergic rhinitis
and to identify its signiﬁcant correlates.
METHODS: A diverse population of 14,000 employees
afﬁliated with 10 western U.S. employers were asked to
participate in a study of allergic rhinitis. The anonymous,
cross-sectional, self-administered questionnaire was 
distributed at the worksite and returned to a third party 
to ensure conﬁdentiality. The instrument included items
assessing allergy severity/symptomatology, medication
use, health service utilization, knowledge and practices,
sociodemographics and reduced productivity (due to full
and partial missed days and presenteeism). The response
rate was 38%, with 2,493 reporting that they currently
had eye or nose allergies.
